Joshua Zeichner, MD on treating aging before it becomes visible
The dermatologist explains why prevention, proven ingredients, and consistency are replacing the search for a single fix.
JOSHUA ZEICHNER STAFFTurn your social into search
We turn your posts into editorial stories that bring new search traffic to zeichnerdermatology.com. Three of yours will be on this page.
Book a demo
joshzeichnermd What if we stopped waiting for visible aging to start treating it? In this week’s In Practice, Joshua Zeichner, MD @joshzeichnermd, shares how his approach to cosmetic dermatology is evolving, from introducing skin tightening earlier to prioritizing proven ingredients over skincare fads. He also weighs in on what practices should be thinking about when it comes to natural looking results, patient expectations, consistency, and the future of regenerative aesthetics. One takeaway? There’s no magic bullet. Meaningful results come from consistency, prevention, and a thoughtful combination of treatments. Read Dr. Zeichner’s full In Practice on BeautyRep.com
The dermatologist explains why prevention, proven ingredients, and consistency are replacing the search for a single fix.
JOSHUA ZEICHNER STAFFHow it works
Same as today. Nothing changes on Instagram.
We turn your post into a full story in your voice within the hour.
One click publishes it to zeichnerdermatology.com. Nothing goes live without you.
Your stories
Nothing was published anywhere. You decide that. Every word will come from your own posts, your own photos and your own treatments.
In Practice · From your post
The dermatologist explains why prevention, proven ingredients, and consistency are replacing the search for a single fix.
“What if we stopped waiting for visible aging to start treating it? In this week’s In Practice, Joshua Zeichner, MD @joshzeichnermd, shares how his approach to cosmetic dermatology is evolving, from introducing skin tightening earlier to prioritizing proven ingredients over skincare fads. He also weighs in on what practices should be thinking about when it comes to natural looking results, patient expectations, consistency, and the future of regenerative aesthetics. One takeaway? There’s no magic bullet. Meaningful results come from consistency, prevention, and a thoughtful combination of treatments. Read Dr. Zeichner’s full In Practice on BeautyRep.com”
Education Series · From your post
We are joining Karan Lal, DO, MS, FAAD for a live discussion on topical therapy and real world patient challenges.
“✨ ZORYVE® (roflumilast). A Case Based Perspective ✨ Join Josh Zeichner, MD and Karan Lal DO, MS, FAAD for a discussion on the latest innovations in topical therapies and the role of ZORYVE in addressing real world patient challenges. 🗓️ Tuesday, August 25th ⏰ 8.00 PM EDT Topics include. • Advancing the dialogue around topical therapy • ZORYVE. Designed with purpose and patients in mind • Real skin. Real challenges. Real results with ZORYVE Sponsored by Arcutis Biotherapeutics 👉 Register now. Link in bio! #ZORYVE #Dermatology #Dermatologist #SES[secret hidden. carrier 2]”
Skincare Education · From your post
We are hosting an evening session on the newest ingredients, data, and product launches, with a live Q&A to follow.
“🌟What’s Trending in Skincare🌟 Stay ahead of the latest developments in dermatology with an evening of expert insights on the newest data, breakthrough ingredients, and innovative product launches shaping patient care! 👨⚕️ Presented by. Dr. Josh Zeichner 🗓️ Tuesday, August 18 🕗 8.00 PM ET 👉 Register now. Link in bio! 💙 Thank you to our sponsors, including Beiersdorf, Bubble, Organon Dermatology, Neutrogena, and Arcutis! #SES[secret hidden. carrier 2] #DermatologyAuthority #Dermatologists #Dermatology”
One social post becomes another searchable entry point to Joshua Zeichner.
Our own magazine. Clicks and citations from Google Search Console, as of September 15, 2026.
Draft story for zeichnerdermatology.com · In Practice
The dermatologist explains why prevention, proven ingredients, and consistency are replacing the search for a single fix.
Joshua Zeichner, MD asks a simple question that reframes how cosmetic dermatology gets practiced: what if we stopped waiting for visible aging to start treating it. As Director of Cosmetic and Clinical Research and Associate Professor of Dermatology at Mount Sinai Hospital, he has spent his career watching patients arrive once lines and laxity are already established, and he is now pushing that timeline earlier.
That shift shows up most clearly in how he talks about skin tightening. Rather than treating it as a late stage correction, he is introducing it sooner, before visible aging has fully set in. The logic is straightforward: addressing structural changes early tends to produce more natural, less dramatic outcomes than trying to reverse years of accumulated change all at once.
Dr. Zeichner is also direct about skincare fads. His stated priority is proven ingredients over whatever is currently trending, a distinction that matters more than it sounds. Trends move quickly and often outpace the research behind them, while ingredients with a real evidence base tend to deliver results that hold up over time, even if they are less exciting to market.
That same evidence based thinking extends to how he defines success with patients. Natural looking results depend on managing expectations from the first conversation, not just technique in the treatment room. Patients need a realistic sense of what a treatment can and cannot do, and consistency between visits matters as much as the choice of procedure itself.
The clearest takeaway from his current approach is that there is no magic bullet. Meaningful results come from consistency, prevention, and a thoughtful combination of treatments working together, not from any one product or procedure carrying the whole outcome. That framing shapes how he builds a plan for each patient rather than defaulting to a single popular treatment.
It also shapes how he thinks about where the field is heading. Regenerative aesthetics, the category focused on encouraging skin to repair and rebuild itself rather than simply masking change, is part of that future. His interest in it fits the same pattern running through his approach: favor what works over time instead of what works immediately.
For other practices, his perspective offers a useful checklist. Think about natural looking results as a planning problem, not just a technical one. Set patient expectations early. Treat consistency as part of the protocol, not an afterthought. And weigh new ingredients or procedures against actual evidence before folding them into a treatment plan.
None of this depends on urgency or a single dramatic intervention. It depends on starting earlier, staying consistent, and trusting combinations of proven approaches over time. That is the practical shift behind the question he opens with, and it is one worth sitting with before the next appointment, not after the signs of aging are already impossible to ignore.
Draft story for zeichnerdermatology.com · Education Series
We are joining Karan Lal, DO, MS, FAAD for a live discussion on topical therapy and real world patient challenges.
On Tuesday, August 25th at 8:00 PM EDT, we are sitting down with Karan Lal, DO, MS, FAAD for a case based conversation on ZORYVE (roflumilast) as part of the Skincare Education Symposium. This is not a product pitch. It is a working discussion between two clinicians about what topical therapy looks like when it meets an actual patient in an actual exam room.
The format matters here. Rather than a general overview of topical treatment options, the session is built around cases, the kind of decisions dermatologists make daily when a standard approach does not quite fit. That structure gives the conversation room to get specific about where a therapy like ZORYVE fits into a broader treatment plan.
Dermatology education often defaults to broad strokes, general mechanisms, general patient types, general outcomes. A case based approach forces something more useful: a real presentation, a real set of constraints, and a real decision about what to try next. That is the structure we are using for this session, and it is why we think it holds up better than a standard lecture format.
The topics laid out for the evening follow that same logic. One centers on advancing the dialogue around topical therapy generally, another looks at how ZORYVE was designed with purpose and patients in mind, and the third gets directly into real skin, real challenges, and real results. Each builds on the last rather than repeating the same ground from a different angle.
Karan Lal brings a perspective shaped by his own patient population, and pairing that with our own clinical experience is the point of doing this as a discussion rather than a solo presentation. Two dermatologists comparing notes on the same drug, from two different practices, tends to surface more practical detail than either one talking alone would.
The session is sponsored by Arcutis Biotherapeutics, the company behind ZORYVE, which is worth naming plainly rather than glossing over. That sponsorship is what makes an event like this possible, and it does not change the fact that the actual content on screen is a clinical discussion between practicing dermatologists, not a scripted advertisement.
Registration is open now, with the link available through our bio, and the session runs live at 8:00 PM EDT on August 25th. For clinicians who treat patients where topical options have felt limited, or who are curious how another practice is thinking through the same cases, this is built to be watched live rather than summarized secondhand.
What stands out about this particular pairing of speakers and format is the willingness to get granular in a live setting, where questions can shape the direction of the conversation as it happens. That is a different kind of value than a written overview can offer, and it is the reason we are doing this as a live session rather than a static resource.
Draft story for zeichnerdermatology.com · Skincare Education
We are hosting an evening session on the newest ingredients, data, and product launches, with a live Q&A to follow.
Skincare moves fast. New ingredients get press before there is real data behind them, product launches arrive weekly, and patients often ask about a trend before we have had a chance to evaluate it ourselves. That gap between what is circulating and what is actually supported by evidence is exactly what we built this session to close, in a format that leaves room for real questions.
We are hosting What's Trending in Skincare on Tuesday, August 18 at 8:00 PM ET, an evening built around the newest data, breakthrough ingredients, and product launches shaping patient care right now. The idea is not to chase headlines but to slow down and actually look at what the current research supports, what is marketing, and what belongs in a real routine.
The session is presented as a straight walk through what is currently shaping dermatology conversations, from ingredient trends to new formulations reaching shelves. Rather than treating each topic as a headline, we are breaking down the reasoning behind it: why an ingredient is gaining attention, what the data actually shows, and where a product launch fits into an established routine versus where it is simply new.
A live Q&A follows the main presentation, which is the part we think matters most. Trend conversations tend to raise more questions than they answer, and a live format lets those get addressed directly instead of sitting unresolved. Anyone attending can bring their own questions about ingredients, product choices, or things they have seen circulating and get a direct answer in real time.
An evening like this only works with the right partners in the room, and we are glad to have support from Beiersdorf, makers of Eucerin and Aquaphor, along with Bubble, Arcutis Biotherapeutics, Organon Dermatology, and Neutrogena. Their involvement reflects a shared interest in getting accurate skincare information in front of people, rather than letting trends get explained secondhand or stripped of context.
Each of these companies sits somewhere in the current skincare conversation already, whether through longstanding drugstore staples or newer dermatologist developed lines. Having them attached to the session means the discussion draws from a wider view of the market, not just one corner of it, which is useful when the goal is genuinely explaining what is trending and why.
August is a reasonable moment to take stock. Product launches tend to cluster earlier in the year, ingredient trends have had time to either hold up or fade, and enough new data has usually surfaced to say something concrete rather than speculative. An evening session also fits naturally into a Tuesday, without asking anyone to rearrange a full day around it.
Registration is open now through the link in our bio, and the session runs live at 8:00 PM ET on August 18. Whether the interest is the newest ingredients, what is actually behind a viral product, or simply wanting a clearer read on where skincare is heading next, the format is built to answer that directly, then open the floor for whatever question comes next.
Keep reading